검색어: hæmostase (덴마크어 - 영어)

hæmostase
hemostasis

effekt på hæmostase:
effect on haemostasis:

embolisering med henblik på hæmostase
hemostatic embolization

· spontant eller farmakologisk nedsat hæmostase
· spontaneous or pharmacological impairment of haemostasis

hæmostase blev opretholdt i hele studiets varighed.
haemostasis was maintained throughout the study duration.

hæmostase blev opretholdt under hele studiets varighed.
haemostasis was maintained throughout the study duration.

et vigtigt sekundært effektmål er opnåelse af hæmostase.
a key secondary endpoint is the restoration of haemostasis.

dosisinterval initialt 2- 3 timer for at opnå hæmostase.
dose interval initially 2 - 3 hours to obtain haemostasis.

evicel er også indiceret som suturunderstøttelse af hæmostase ved karkirurgi.
evicel is also indicated as suture support for haemostasis in vascular surgery.

man bør overveje en passende behandling heraf, såsom hæmostase,
initiation of appropriate therapy such as surgical haemostasis, blood replacements, fresh plasma transfusion, plasmapheresis should be considered.

der bør gives mindst 3 doser for at opnå effektiv hæmostase.
at least three doses should be administered to secure effective haemostasis.

man bør overveje en passende behandling heraf, såsom hæmostase, m
initiation of appropriate therapy such as surgical haemostasis, blood ed

startdosis bør gives 6 timer postoperativt, forudsat der er tilfredsstillende hæmostase.
the initial dose should be given 6 hours following surgical closure provided that haemostasis has been established.

startdosis bør gives 6 timer postoperativt, forudsat der er tilfredsstillende hæmostase. idl
the initial dose should be given 6 hours following surgical closure provided that haemostasis has been established. ici

hvis nedsat leverfunktion ledsages af koagulopati, se informationen vedr. virkningen på hæmostase.
in case hepatic impairment is accompanied by coagulopathy see the information on the effect on haemostasis.

patienter (< 3 dage), og først når der er tilfredsstillende kirurgisk hæmostase. ikk
agents that may enhance the risk of haemorrhage should not be administered concomitantly with lp

farmakoterapeutisk klassifikation: hæmostase til lokalbrug, atc-kode: b02bc30, kombinationer virkningsmekanisme
pharmacotherapeutic group: local haemostatics, atc code: b02bc30 combinations mechanism of action

må ikke gives, med mindre der er tilfredsstillende hæmostase (se pkt.4. 4) . ge
the injection should not be given unless haemostasis has been established (see section 4.4) . ici

injektionen må ikke gives, med mindre der er tilfredsstillende hæmostase (se pkt.4. 4) .
the injection should not be given unless haemostasis has been established (see section 4.4) .

antifibrinolytisk behandling (aminokapronsyre eller cyklokapron) og/eller rekombinant faktor viia kan øge hæmostase.
antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor viia may increase haemostasis.